University of Kentucky offers stroke stem cell trial

The University of Kentucky will be the first site in the state and one of a select few in the entire country participating in the first stages of a groundbreaking study to investigate the effects of MultiStem, a human adult stem cell product, on patients with acute ischemic stroke. The phase II clinical trial, known as Atherys stroke protocol B01-02, was recently approved by UK's institutional review board.

" may have great potential in stroke treatment, and we need to approach it scientifically. We are excited to be the first to bring a clinical trial of stem cells for stroke to Kentucky," said Dr. Michael Dobbs, director of the UK HealthCare Stroke Affiliate Network and principal investigator on the stem cell trial.

Despite recent advances in interventional ischemic stroke treatment, medical therapy for the treatment of stroke has largely been limited to tPA, the clot-busting drug that received FDA approval in 1996.

Using stem cells in the treatment of stroke represents a novel approach to treating the damage caused by stroke. Studies of animal models suggest that stem cell therapy may offer a unique neuro-protective effect, and further investigation as to the mechanism of this benefit is currently underway.

MultiStem is also being studied as a potential treatment for a variety of diseases, with the therapy already successfully completing a Phase I trial in patients suffering from Graft Versus Host Disease (GVHD), a potentially deadly complication of in cancer patients.

"UK's selection as one of the first sites for this study exemplifies our position as a national leader in cutting edge and research. By pioneering new approaches to , we are doing our part to ensure that our stroke patients receive the absolute best care possible," Dobbs said.

Provided by University of Kentucky

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Bone marrow stem cell therapy safe for acute stroke: report

Aug 31, 2011

Using a patient's own bone marrow stem cells to treat acute stroke is feasible and safe, according to the results of a ground-breaking Phase I trial at The University of Texas Health Science Center at Houston (UTHealth).

Recommended for you

Cause of ageing remains elusive

21 hours ago

A report by Chinese researchers in the journal Nature a few months ago was a small sensation: they appeared to have found the cause for why organisms age. An international team of scientists, headed by the ...

Newly discovered bacterial defence mechanism in the lungs

23 hours ago

A new study from Karolinska Institutet presents a previously unknown immunological mechanism that protects us against bacterial infections in the lungs. The study is being published in the American Journal of Respiratory an ...

User comments